December 6, 2017

Neumentum, a pharmaceutical company dedicated to transforming the way acute and chronic pain are treated – without opioids – announced that is has raised $6 million in a Series A funding round through the sale of Series A Convertible Preferred Stock.  The funding will be used to advance a pipeline of non-opioid drug candidates that have the potential to treat pain, without the risks of abue, misuse and diversion frequently associated with opioids.  Learn more here.


Donate today!


Personal Info

Donation Total: $100